Allogene Therapeutics (NASDAQ:ALLO) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Posted by Stanley Muller on May 13th, 2026

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01, FiscalAI reports.

Allogene Therapeutics Trading Up 1.3%

NASDAQ:ALLO traded up $0.03 during trading hours on Wednesday, hitting $2.33. The stock had a trading volume of 6,374,343 shares, compared to its average volume of 8,395,777. The business has a 50 day simple moving average of $2.40 and a two-hundred day simple moving average of $1.84. The company has a market cap of $570.43 million, a PE ratio of -2.68 and a beta of 0.46. Allogene Therapeutics has a 1-year low of $0.86 and a 1-year high of $4.46.

Wall Street Analysts Forecast Growth

ALLO has been the subject of a number of research reports. Truist Financial upgraded Allogene Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Piper Sandler boosted their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Allogene Therapeutics in a report on Friday, May 1st. Citizens Jmp boosted their target price on Allogene Therapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Tuesday, April 14th. Finally, JPMorgan Chase & Co. raised shares of Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a report on Thursday, April 16th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Allogene Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $8.44.

Read Our Latest Stock Report on Allogene Therapeutics

Insider Transactions at Allogene Therapeutics

In related news, CEO David D. Chang sold 47,763 shares of Allogene Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $2.47, for a total value of $117,974.61. Following the completion of the sale, the chief executive officer owned 5,150,599 shares in the company, valued at approximately $12,721,979.53. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 72,183 shares of company stock worth $177,771. 13.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Allogene Therapeutics by 9.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,020,770 shares of the company’s stock worth $11,186,000 after buying an additional 761,642 shares in the last quarter. Primecap Management Co. CA raised its stake in shares of Allogene Therapeutics by 15.0% in the 4th quarter. Primecap Management Co. CA now owns 8,139,840 shares of the company’s stock worth $11,152,000 after buying an additional 1,060,532 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Allogene Therapeutics by 177.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after purchasing an additional 3,747,397 shares in the last quarter. Patient Square Capital LP lifted its stake in Allogene Therapeutics by 66.5% during the fourth quarter. Patient Square Capital LP now owns 4,963,756 shares of the company’s stock valued at $6,800,000 after purchasing an additional 1,982,360 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Allogene Therapeutics by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 3,932,910 shares of the company’s stock worth $5,389,000 after acquiring an additional 99,025 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.